Features of the humoral response to immunization "Gam-COVID-Vac" and in patients with COVID-19-Reference-Cited by-同舟云学术

Features of the humoral response to immunization "Gam-COVID-Vac" and in patients with COVID-19

Published:2022-04-17 Issue:4 Volume:67 Page:227-233
ISSN:2412-1320
Container-title:Russian Clinical Laboratory Diagnostics
language:
Short-container-title:Klin. lab. diagn.

Author:

Akinshina Yuliya Aleksandrovna¹^ORCID,Mardanly S. G.²^ORCID,Rotanov S. V.³^ORCID,Pomazanov V. V.⁴^ORCID,Kiseleva V. A.⁵^ORCID,Ermolaev I. I.I.¹^ORCID

Affiliation:

1. CJSC «EKOlab»

2. CJSC «EKOlab»; «First Moscow State Medical University after I.M. Sechenov» of the Ministry of Healthcare of the Russian Federation (1st MSMU after I.M. Sechenov); State educational institution of higher education of the Moscow region «State Humanitarian University of Technology» (GGTU)

3. CJSC «EKOlab»; State budgetary healthcare institution оf Moscow region «Liuberetskiy kozhno-venerologicheskiy dispanser»

4. CJSC «EKOlab»; State educational institution of higher education of the Moscow region «State Humanitarian University of Technology» (GGTU)

5. State educational institution of higher education of the Moscow region «State Humanitarian University of Technology» (GGTU)

Abstract

The paper present the results of a survey of people who have undergone immunization with a combined vector vaccine for the prevention of coronavirus infection COVID-19 «Sputnik V - Gam-COVID-Vac», as well as COVID-19 recovalents. Using a quantitative enzyme-linked immunosorbent assay, the levels of specific IgG were determined in persons who had had different degrees of severity before vaccination, in persons who were immuno-negative before immunization, as well as in convalescents who had undergone coronavirus infection of varying severity. The immunological targeting of antibodies against various SARS-CoV-2 proteins is considered.

Publisher

EKOlab

Subject

Biochemistry (medical),Medical Laboratory Technology,General Medicine

Reference34 articles.

1. Krammer F., Simon V. Serology assays to manage COVID-19. Science. 2020; 368: 1060-1. https://doi.org/10.1126/science.abc1227

2. Alter G., Seder R. The power of antibody-based surveillance. The New England Journal of Medicine. 2020; 383: 1782-4. https://doi.org/10.1056/NEJMe2028079

3. Abu Jabal K., Ben-Amram H., Beiruti K., Batheesh Y., Sussan C., Zarka S. et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the bnt162b2 mrna COVID-19 vaccine: Real-world evidence from healthcare workers, Israel, december 2020 to january 2021. Eurosurveillance. 2021; 26(6): 2100096. https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096

4. Prendecki M., Clarke C., Brown J., Cox A., Gleeson S., Guckian M. et al. Effect of previous SARS-CоV-2 infection on humoral and t-cell responses to single-dose bnt162b2 vaccine. Lancet. 2021; 397(10280): 1178-81. https://doi.org/10.1016/S0140-6736(21)00502-X

5. Jin P., Li J., Pan H., Wu Y., Zhu F. Immunological surrogate endpoints of covid-2019 vaccines: The evidence we have versus the evidence we need. Signal Transduction and Targeted Therapy. 2021; 6: 48. https://doi.org/10.1038/s41392-021-00481-y